Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Amortization - Goodwill Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased

Mesa Laboratories (MLAB) Long-Term Debt Repayments (2016 - 2025)

Mesa Laboratories (MLAB) has disclosed Long-Term Debt Repayments for 15 consecutive years, with $84.1 million as the latest value for Q4 2025.

Quarterly Long-Term Debt Repayments rose 53.84% to $84.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $97.5 million through Dec 2025, up 17.39% year-over-year, with the annual reading at $71.6 million for FY2025, 113.61% up from the prior year.
Long-Term Debt Repayments hit $84.1 million in Q4 2025 for Mesa Laboratories, up from $5.9 million in the prior quarter.
In the past five years, Long-Term Debt Repayments ranged from a high of $84.1 million in Q4 2025 to a low of -$54.7 million in Q3 2024.
Historically, Long-Term Debt Repayments has averaged $16.2 million across 5 years, with a median of $9.0 million in 2021.
Biggest YoY gain for Long-Term Debt Repayments was 794.5% in 2024; the steepest drop was 583.56% in 2024.
Year by year, Long-Term Debt Repayments stood at $10.0 million in 2021, then fell by 20.0% to $8.0 million in 2022, then soared by 175.0% to $22.0 million in 2023, then skyrocketed by 148.57% to $54.7 million in 2024, then skyrocketed by 53.84% to $84.1 million in 2025.
Business Quant data shows Long-Term Debt Repayments for MLAB at $84.1 million in Q4 2025, $5.9 million in Q3 2025, and $7.4 million in Q2 2025.